JAM2

Across TCGA pan-cancer cohorts, JAM2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated JAM2 data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher JAM2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JAM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where JAM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.952	0.488	.006	21	view →
CCRCC	OS	Median	All	1.000	0.592	.005	19	view →
PDAC	DFS	Median	II,III,IV	0.325	0.955	.012	12	view →
LUAD	DFS	Quartile	All	0.651	0.394	.023	6	view →
LSCC	OS	Quartile	II,III,IV	0.672	1.000	.019	4	view →
GBM	DFS	Quartile	All	0.481	0.243	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

JAM2–HNSC (DFS)

Open the HNSC breakdown →